Onctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in the randomized Phase I/II study investigating lead ...

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Regular physical activity helps cancer patients manage fatigue, pain, brain fog, emotional distress, and heart damage during ...

The development of second tumors is influenced by several factors. These include the type and intensity of treatment received ...

Patients with advanced non-small cell lung cancer and uncommon EGFR mutations lived almost twice as long without disease ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations.

cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as skin, lung ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.